Keyword: Bristol-Myers Squibb
Human Longevity CFO/COO departs after scandal; Sangamo loses another top executive; McCann Health fires chief creative for conduct violation and more.
Gritstone Oncology and Bristol-Myers Squibb will start a phase 1 trial of a combination immunotherapy by year end.
IFM Therapeutics is hiving off its NLRP3 stable into a subsidiary dubbed IFM Tre, which expects to advance its lead asset into phase 1 next year.
BMS is combining Opdivo and cabiralizumab, an anti-CSF-1 antibody, with Apexigen’s lead CD40 activator in an early-phase solid tumor study.
Idera Pharmaceuticals' TLR antagonist, IMO-8400, failed to improve skin symptoms in adults with dermatomyositis.
Enyo Pharma raised nearly $47 million to launch the first two phase 2 clinical trials of EYP001, its lead candidate in hep B and NASH, before 2019.
Nektar’s much-anticipated data from a study pairing its NKTR-214 with Bristol-Myers Squibb’s Opdivo have resulted in a lot of head-scratching.
Using an old Roche drug, Madrigal Pharmaceuticals has seen its stock soar 130% on its latest fatty liver disease trials data.
Lilly’s oncology chief is retiring; a GSK vet is launching a Chinese public health startup; and Gilead’s R&D chief is going back to his roots.
Curis is bringing on board member Robert Martell, formerly CMO at Tesaro, as a full-time employee in the newly created role to head its R&D.